Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04625946 · ClinicalTrials.gov registry record · Phase 4
Metformin as an Adjunctive Therapy to Catheter Ablation in Atrial Fibrillation
A Phase 4 study of Atrial Fibrillation, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 4
- Development phase
- 117
- Enrollment target
- 1
- Study location
NCT04625946: Completed Phase 4 study of Atrial Fibrillation, sponsored by University of Michigan.
NCT04625946 is a Phase 4 study of Atrial Fibrillation that has completed, run by University of Michigan. The registered enrollment target is 117 participants, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04625946, a Phase 4 study of Atrial Fibrillation, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 117 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial is being done to determine if metformin, a drug which is normally used in diabetes, can reduce atrial fibrillation in patients who are having an ablation for atrial fibrillation (AF). Atrial fibrillation is an abnormal heart rhythm which research has shown is related in part to obesity and diabetes. It is anticipated that the participants treated in the metformin arm will have greater freedom from recurrent atrial arrhythmias after ablation. Eligible participants enrolled in the trial will be assigned to one of the treatment arms (no treatment or metformin) and have follow-up visits up to approximately 1 year after the ablation. Additionally, all patients will also receive education on lifestyle changes and exercise which are standard of care.
Primary Outcome
There will be a 3 month blanking period after ablation during which recurrent atrial arrhythmias will not contribute to the primary endpoint.
Conditions Studied
Interventions
- DRUG Metformin
- DEVICE AliveCor
- BEHAVIORAL Recommendations for lifestyle modification.
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2021-01-19 |
| Est. Completion | 2025-08-10 |
| Phase | Phase 4 |
What the finished NCT04625946 record still lists
NCT04625946 is an interventional study that assigns participants to a tested intervention. The registered 117 participants enrollment target is mid-sized for trials with a published cap, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 3 interventions - of which Metformin is the first listed.
NCT04625946 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT04625946 about?
NCT04625946 is a clinical study titled "Metformin as an Adjunctive Therapy to Catheter Ablation in Atrial Fibrillation". This clinical trial is being done to determine if metformin, a drug which is normally used in diabetes, can reduce atrial fibrillation in patients who are having an ablation for atrial fibrillation (AF). Atrial fibrillation is an abnormal heart rhythm which research has shown is related in part to o...
What is the current status of trial NCT04625946?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 117 participants. The study started on 2021-01-19. Estimated completion is 2025-08-10.
What conditions does trial NCT04625946 study?
This clinical trial studies the following conditions: Atrial Fibrillation.
What interventions are being tested in trial NCT04625946?
The interventions under investigation include: Metformin (DRUG), AliveCor (DEVICE), Recommendations for lifestyle modification. (BEHAVIORAL).
Who is sponsoring clinical trial NCT04625946?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04625946 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04625946's enrollment target sits among peer trials
117 136th of 202 higher than 67 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
RECRUITING · Phase 4
-
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
RECRUITING · Phase 4
-
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
RECRUITING · Phase 4
-
Ondansetron for the Management of Atrial Fibrillation
RECRUITING · Phase 4
-
EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)
ACTIVE NOT RECRUITING · Phase 4
-
Therapeutic Initial Heparin Dosing for Patients With Clots or Certain Heart Conditions Admitted to the Hospital
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03539822 · 117 participants · Phase 1
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- NCT03786692 · 117 participants · Phase 2
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
- NCT04479696 · 117 participants · NA
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
- NCT04940585 · 117 participants · NA
ROSE in Sunset Park
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI